Cannabis for Epilepsy & Seizures - Evidence-Based Guide | MarijuanaHealth
Back to Conditions

Cannabis for Epilepsy & Seizures

Strong Evidence

FDA-Approved CBD Therapy · 90,000+ monthly searches · Last updated: April 2026

EpidiolexDravet SyndromeLennox-GastautAnticonvulsantCBD PharmacologyTreatment-Resistant Epilepsy
Executive Summary
41–44%
Seizure Frequency Reduction (Epidiolex RCTs)
2018
FDA Approval Year for Epidiolex
3.4M
Americans Living with Epilepsy

Evidence Rating: Strong

Epilepsy represents the strongest evidence base in cannabinoid medicine. Epidiolex (pharmaceutical-grade CBD) received FDA approval in 2018 for Dravet syndrome and Lennox-Gastaut syndrome — making it the first plant-derived cannabinoid medicine approved by the FDA. Multiple Phase III RCTs demonstrate significant, clinically meaningful seizure reduction. Evidence for THC-containing cannabis in epilepsy is more limited and complex.

Key Findings:

  • Epidiolex (CBD) is FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex
  • Phase III RCTs show 41–44% reduction in convulsive seizure frequency vs placebo
  • 5% of Epidiolex-treated patients achieved complete seizure freedom in trials
  • CBD anticonvulsant mechanisms are distinct from and complementary to existing AEDs
  • THC may have pro-convulsant effects at high doses — THC-dominant cannabis is not recommended for epilepsy
  • CBD interacts significantly with clobazam, valproate, and other AEDs — requires therapeutic drug monitoring
  • Artisanal CBD products lack pharmaceutical-grade purity and dosing precision of Epidiolex
  • Ongoing trials investigating CBD for other epilepsy syndromes including CDKL5 and Angelman syndrome

Understanding Epilepsy & Seizure Disorders

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures — episodes of abnormal electrical activity in the brain. It affects approximately 3.4 million Americans and 65 million people worldwide, making it one of the most common serious neurological conditions. While many patients achieve seizure control with anti-epileptic drugs (AEDs), approximately 30% have treatment-resistant epilepsy — defined as failure of two or more appropriate AED trials — and it is primarily this population that has driven cannabinoid research.

The journey of cannabis in epilepsy medicine is one of the most compelling in modern pharmacology. Parent-led advocacy — most famously the story of Charlotte Figi and Charlotte's Web CBD oil — preceded and ultimately catalyzed the rigorous clinical trials that led to FDA approval of Epidiolex in 2018. This trajectory from anecdote to Phase III RCT to regulatory approval represents a model for evidence-based cannabinoid medicine development.

Dravet Syndrome

Severe, treatment-resistant epilepsy beginning in infancy, caused by SCN1A gene mutations. Characterized by prolonged febrile seizures, multiple seizure types, and developmental regression. Affects 1 in 15,700 people. First FDA-approved indication for Epidiolex.

Lennox-Gastaut Syndrome (LGS)

Severe childhood-onset epilepsy with multiple seizure types including drop attacks (atonic seizures), tonic seizures, and absence seizures. Associated with intellectual disability. Second FDA-approved indication for Epidiolex.

Tuberous Sclerosis Complex (TSC)

Genetic disorder causing benign tumors in multiple organs including the brain, leading to treatment-resistant epilepsy in 85% of patients. Third FDA-approved indication for Epidiolex (approved 2020). Seizures often begin in infancy.

Treatment-Resistant Epilepsy

Defined as failure of two or more appropriately chosen and tolerated AED trials. Affects ~30% of all epilepsy patients. This population has the greatest unmet need and has been the primary focus of cannabinoid clinical trials.

How CBD Works as an Anticonvulsant

CBD's anticonvulsant mechanisms are remarkably diverse and largely distinct from traditional AEDs, which is why it can be effective in treatment-resistant cases and why it has additive effects when combined with existing medications. Unlike THC, CBD has minimal affinity for CB1 and CB2 receptors — its anticonvulsant effects operate through multiple other molecular targets.

TRPV1 Channel Modulation

CBD activates and then desensitizes TRPV1 (transient receptor potential vanilloid 1) channels, which are involved in neuronal excitability and seizure generation. TRPV1 is expressed in hippocampal and cortical neurons — brain regions critically involved in seizure initiation and propagation. This mechanism is particularly relevant to Dravet syndrome, where TRPV1 dysregulation contributes to seizure susceptibility.

GPR55 Antagonism

GPR55 is an orphan G-protein coupled receptor that, when activated, increases neuronal excitability and promotes seizure activity. CBD is a potent GPR55 antagonist — blocking this receptor reduces neuronal hyperexcitability. This mechanism may be particularly important in Dravet syndrome where GPR55 signaling is dysregulated due to SCN1A mutations.

Adenosine Reuptake Inhibition

Adenosine is an endogenous anticonvulsant neuromodulator that reduces neuronal excitability. CBD inhibits adenosine reuptake transporters, increasing extracellular adenosine levels in the brain. This mechanism enhances the brain's natural seizure-suppressing system and may contribute to CBD's broad-spectrum anticonvulsant activity across multiple epilepsy syndromes.

Sodium Channel Modulation

CBD modulates voltage-gated sodium channels — the same target as many traditional AEDs including valproate and carbamazepine. CBD stabilizes the inactivated state of sodium channels, reducing repetitive neuronal firing. This mechanism is especially relevant in Dravet syndrome, which is caused by loss-of-function mutations in SCN1A (Nav1.1 sodium channel subunit).

Clinical Research & FDA Approval Evidence

The clinical evidence for CBD in epilepsy is the most robust in all of cannabinoid medicine, anchored by multiple Phase III randomized controlled trials that directly supported FDA approval of Epidiolex. These trials set the gold standard for cannabinoid clinical research.

Devinsky et al. (2017) — Dravet Syndrome Phase III RCT
Strong
New England Journal of Medicine120 patients, double-blind RCT

Landmark Phase III trial of Epidiolex (20mg/kg/day CBD) in Dravet syndrome. Median convulsive seizure frequency reduced by 38.9% in CBD group vs 13.3% placebo (p=0.01). 5% of CBD patients achieved seizure freedom vs 0% placebo. 43% of CBD patients had ≥50% seizure reduction. This trial was pivotal in the FDA approval of Epidiolex. Published in the New England Journal of Medicine — the highest-impact medical journal.

Thiele et al. (2018) — Lennox-Gastaut Phase III RCT
Strong
The Lancet225 patients, double-blind RCT

Phase III trial of Epidiolex in Lennox-Gastaut syndrome. Drop seizure frequency reduced by 41.9% (20mg/kg/day) and 37.2% (10mg/kg/day) vs 17.2% placebo. Both doses statistically superior to placebo (p<0.0001). Confirmed efficacy across the full spectrum of LGS seizure types. Published in The Lancet, directly supporting FDA approval.

Devinsky et al. (2018) — Tuberous Sclerosis Complex
Strong
The Lancet Neurology148 patients, double-blind RCT

Phase III trial of Epidiolex in TSC-associated epilepsy. TSC seizure frequency reduced by 48.6% (25mg/kg/day) and 47.5% (50mg/kg/day) vs 26.5% placebo. Both doses significantly superior to placebo. Led to FDA approval of Epidiolex for TSC in 2020, expanding the approved indications.

Devinsky et al. (2016) — Open-Label Expanded Access
Moderate
The Lancet Neurology214 patients, open-label

Expanded access program providing Epidiolex to treatment-resistant epilepsy patients prior to FDA approval. Median seizure frequency reduced by 36.5% across all epilepsy types. Dravet syndrome patients showed 50% reduction. Established safety profile and provided early efficacy signal that supported Phase III trial design.

Szaflarski et al. (2018) — Real-World Registry Data
Moderate
Epilepsy & Behavior607 patients, registry study

University of Alabama CBD program registry analyzing real-world outcomes. 45% of patients reported ≥50% seizure reduction. Improvements in sleep, alertness, and quality of life reported by caregivers. Adverse effects including somnolence and elevated liver enzymes consistent with RCT data. Confirmed real-world effectiveness mirrors clinical trial results.

Press et al. (2015) — Artisanal CBD Products
Emerging
Epilepsy & Behavior75 children, survey study

Survey of families using artisanal CBD-enriched cannabis for pediatric epilepsy. 85% reported reduction in seizure frequency. However, significant variability in product composition, dosing, and outcomes. Highlighted the need for pharmaceutical-grade standardized CBD products — ultimately fulfilled by Epidiolex.

Epidiolex vs. Artisanal CBD Products

A critical distinction for epilepsy patients and families is the difference between FDA-approved Epidiolex and the wide range of commercially available CBD oils, tinctures, and supplements. These are not interchangeable products.

Epidiolex (FDA-Approved)
  • Pharmaceutical-grade 99%+ pure CBD isolate in sesame oil
  • Precisely dosed at 100mg/mL concentration
  • Manufactured under strict GMP (Good Manufacturing Practice) standards
  • Proven efficacy in Phase III RCTs for specific syndromes
  • Established safety profile from 1,500+ patient trials
  • Requires neurologist prescription and monitoring
  • Covered by insurance for approved indications
  • Consistent batch-to-batch potency verified by FDA
Artisanal CBD Products
  • Variable CBD concentration — often mislabeled by 20–40%
  • May contain THC (potentially pro-convulsant)
  • No GMP manufacturing requirements
  • No RCT evidence for specific epilepsy syndromes
  • Unknown long-term safety profile
  • Available OTC without medical supervision
  • Not covered by insurance
  • Batch-to-batch variability in potency and composition

Epidiolex Dosing Protocols

Dravet Syndrome
Starting Dose
2.5 mg/kg twice daily (5 mg/kg/day)
Target Dose
10 mg/kg twice daily (20 mg/kg/day)
Maximum Dose
10 mg/kg twice daily (20 mg/kg/day)

Titration: Increase by 2.5 mg/kg twice daily every week as tolerated

Higher doses (up to 20mg/kg/day) may provide additional benefit in some patients. Titrate based on seizure response and tolerability.

Lennox-Gastaut Syndrome
Starting Dose
2.5 mg/kg twice daily (5 mg/kg/day)
Target Dose
5–10 mg/kg twice daily (10–20 mg/kg/day)
Maximum Dose
10 mg/kg twice daily (20 mg/kg/day)

Titration: Increase by 2.5 mg/kg twice daily every week. Both 10 and 20 mg/kg/day showed efficacy in trials.

10 mg/kg/day may be preferred initial target to balance efficacy and tolerability. Escalate to 20 mg/kg/day if inadequate response.

Tuberous Sclerosis Complex
Starting Dose
2.5 mg/kg twice daily (5 mg/kg/day)
Target Dose
12.5 mg/kg twice daily (25 mg/kg/day)
Maximum Dose
12.5 mg/kg twice daily (25 mg/kg/day)

Titration: Increase by 2.5 mg/kg twice daily every week. TSC requires higher target dose than Dravet/LGS.

TSC trials used higher doses (25–50 mg/kg/day). FDA-approved dose is 25 mg/kg/day. Monitor liver enzymes closely at higher doses.

Required Monitoring During Epidiolex Treatment

  • Liver function tests (ALT, AST, bilirubin) at baseline, 1 month, 3 months, 6 months, then annually
  • Serum levels of concomitant AEDs — especially clobazam and valproate — at baseline and after dose changes
  • Seizure diary: frequency, duration, and type of all seizure events
  • Somnolence and sedation assessment — particularly when combined with clobazam
  • Weight monitoring — CBD can affect appetite

Drug Interactions with Anti-Epileptic Medications

CBD is a potent inhibitor of CYP2C19 and CYP3A4 liver enzymes, which metabolize many anti-epileptic drugs. These interactions are clinically significant and require therapeutic drug monitoring when Epidiolex is added to existing AED regimens.

Clobazam (Onfi)

High — Requires Dose Adjustment

Most clinically significant interaction. CBD inhibits CYP2C19, which metabolizes clobazam's active metabolite N-desmethylclobazam (norclobazam). Norclobazam levels increase 3–5x when Epidiolex is added, causing excessive sedation, somnolence, and ataxia. Clobazam dose reduction of 25–50% is typically required. Paradoxically, the clobazam interaction may contribute to Epidiolex's anticonvulsant efficacy.

Valproate / Valproic Acid (Depakote)

High — Hepatotoxicity Risk

Combined use significantly increases risk of liver enzyme elevation and hepatotoxicity. In clinical trials, 20% of patients on both Epidiolex and valproate developed elevated liver enzymes vs 3% on Epidiolex alone. More frequent liver function monitoring required. Valproate dose reduction may be necessary. Avoid combination in patients with pre-existing liver disease.

Stiripentol (Diacomit)

Moderate

Stiripentol inhibits CYP3A4 and CYP2C19, the same enzymes CBD inhibits. Combined use may increase CBD plasma levels and risk of adverse effects. Stiripentol also increases clobazam levels — triple combination (CBD + clobazam + stiripentol) requires careful monitoring of all three agents.

Everolimus (Afinitor) — TSC patients

High — Requires Dose Adjustment

TSC patients often receive everolimus (mTOR inhibitor) for seizure control and tumor management. CBD inhibits CYP3A4, which metabolizes everolimus, potentially doubling everolimus blood levels. Everolimus dose reduction and therapeutic drug monitoring are required when Epidiolex is initiated in TSC patients.

Phenytoin / Fosphenytoin

Moderate

CBD inhibits CYP2C9 and CYP2C19, which metabolize phenytoin. May increase phenytoin levels, risking toxicity (nystagmus, ataxia, cognitive impairment). Monitor phenytoin levels when initiating or adjusting CBD dose.

Carbamazepine / Oxcarbazepine

Low-Moderate

Carbamazepine is a potent CYP3A4 inducer that may reduce CBD plasma levels by up to 40%, potentially reducing Epidiolex efficacy. Higher CBD doses may be required. Monitor seizure frequency when carbamazepine is added or removed from the regimen.

Guidance for Patients & Caregivers

Steps to Access Epidiolex
  1. 1Consult a neurologist or epileptologist — Epidiolex requires specialist prescription
  2. 2Document treatment history — confirm failure of ≥2 appropriate AEDs to establish treatment-resistant epilepsy
  3. 3Obtain baseline labs — liver function tests (ALT, AST, bilirubin) required before starting
  4. 4Review all current medications with your neurologist for interaction assessment
  5. 5Contact insurance — Epidiolex is covered by most insurers for FDA-approved indications; patient assistance programs available
  6. 6Start a seizure diary — track frequency, duration, and type before and after starting Epidiolex
  7. 7Schedule follow-up labs at 1 month, 3 months, and 6 months after initiation
Emergency Warning Signs — Call 911 or Go to ER:
  • Status epilepticus — seizure lasting more than 5 minutes or multiple seizures without recovery
  • Sudden increase in seizure frequency or new seizure types after starting Epidiolex
  • Signs of liver toxicity: jaundice (yellowing of skin/eyes), dark urine, severe abdominal pain, unusual fatigue
  • Severe allergic reaction: rash, difficulty breathing, swelling of face or throat
  • Extreme sedation or unresponsiveness — may indicate clobazam toxicity from drug interaction

Ongoing Research & Future Directions

CDKL5 Deficiency Disorder

Phase III trials of Epidiolex in CDKL5 deficiency disorder — a rare genetic epilepsy with early-onset seizures — are underway. Preliminary data from expanded access programs shows promising seizure reduction.

Angelman Syndrome

Clinical trials investigating CBD for epilepsy associated with Angelman syndrome are in progress. The condition shares some mechanistic overlap with Dravet syndrome in terms of GABAergic dysfunction.

PCDH19 Epilepsy

PCDH19 epilepsy is a female-predominant epilepsy syndrome with some clinical similarities to Dravet syndrome. Case series and small studies suggest CBD may be beneficial; formal RCTs are needed.

Focal Epilepsies

Most CBD trials have focused on generalized epilepsy syndromes. Research into CBD for focal (partial) epilepsies — the most common epilepsy type in adults — is an important and underexplored area.

Clinical References & PubMed Citations

[1]Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020. PMID: 28538134
[2]Thiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096. PMID: 29395273
[3]Devinsky O, et al. Cannabidiol in Dravet syndrome study group. Epilepsia. 2018;59(12):2285-2293. PMID: 30426503
[4]Devinsky O, et al. Compassionate use of cannabidiol in children with treatment-resistant epilepsy. Lancet Neurol. 2016;15(14):1307-1315. PMID: 27816399
[5]Szaflarski JP, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018;87:131-136. PMID: 30098576
[6]Press CA, et al. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52. PMID: 25845492
[7]Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70(Pt B):313-318. PMID: 28188044
[8]Lattanzi S, et al. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 2018;78(17):1791-1804. PMID: 30390221